Therefore, a gene therapy vector system that can simultaneously express TK and CD in a cancer-specific manner will be advantageous for treating glioblastomas with inter-tumoral heterogeneity at genetic, proteomic, and epigenetic levels, which often leads to TK or CD resistance via the activation of alternative pathways [4,38]. Here, TKT is linked to glioblastoma.